The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review-Reference-Cited by-同舟云学术

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review

Published:2022-09-13 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Sharaf Joudi,Williams Kerry-Ann D,Tariq Maha,Acharekar Maitri V,Guerrero Saldivia Sara E,Unnikrishnan Sumedha,Chavarria Yeny Y,Akindele Adebisi O,Jalkh Ana P,Eastmond Aziza K,Shetty Chaitra,Rizvi Syed Muhammad Hannan A,Mohammed Lubna

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference31 articles.

1. Overall efficacy and safety of safinamide in Parkinson's disease: a systematic review and a meta-analysis;Giossi R;Clin Drug Investig,2021

2. Prevalence of Parkinson's disease across North America;Marras C;NPJ Parkinsons Dis,2018

3. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: the SYNAPSES trial;Abbruzzese G;J Parkinsons Dis,2021

4. The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson's disease: meta-analysis of randomized controlled trials;Huang YH;Ther Adv Psychopharmacol,2021

5. Comprehensive examination of therapies for pain in Parkinson's disease: a systematic review and meta-analysis;Qureshi AR;Neuroepidemiology,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insomnia in Parkinson’s Disease: Causes, Consequences, and Therapeutic Approaches;Molecular Neurobiology;2024-08-05

2. Potassium and calcium channels in different nerve cells act as therapeutic targets in neurological disorders;Neural Regeneration Research;2024-06-03

3. Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;CNS Drugs;2023-11

4. Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease;Patient Related Outcome Measures;2023-10

5. Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson’s Disease;Current Neuropharmacology;2023-07-31